In general, in comparison with breast and gastric tumors harboring HER2 amplification, these pooled results implicated the possibility that HER2-amplified LUAD establishes a favorable TIME for developing therapeutic efficacy in cancer immunotherapy. The gene discussed is ERBB2; the disease is cancer.